The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.

Transl Oncol · 2022 · PMC8866737 · PMID 35196605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

First, the confirmatory study showed a trend towards excess death despite multiple trial design features that were biased in favor of the melflufen arm.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.